myotonic dystrophy Type 1

Novartis
Biotech

Novartis signs $1.1B deal for muscular dystrophy biotech

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when bought Kate Therapeutics, the pharma’s CEO said.
James Waldron Nov 21, 2024 8:19am
steps race jump stairs climb

PepGen gains a little pep in its step as FDA clears trial hold

Oct 12, 2023 7:00am
Letter opening FDA clinical hold

Awaiting FDA letter, PepGen oligonucleotide no closer to clinic

Jun 14, 2023 9:05am
Stop sign

FDA blocks PepGen's attempt to get 2nd oligonucleotide to clinic

May 31, 2023 8:11am
Photo of a chain being held together by a piece of rope

Avidity says FDA has 'eased' partial hold on lead asset

May 17, 2023 11:16am
Vertex

Vertex pays Entrada $224M for preclinical rare disease drug

Dec 8, 2022 9:06am